{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:55:29Z","timestamp":1782917729050,"version":"3.54.5"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shanghai Jiao Tong University School of Medicine, Shanghai, China","award":["FLT3-ITD-D835Y"],"award-info":[{"award-number":["FLT3-ITD-D835Y"]}]},{"name":"Shanghai Jiao Tong University School of Medicine, Shanghai, China","award":["FLT3-ITD-Y842C"],"award-info":[{"award-number":["FLT3-ITD-Y842C"]}]},{"name":"Shanghai Jiao Tong University School of Medicine, Shanghai, China","award":["FLT3-ITD-F961L"],"award-info":[{"award-number":["FLT3-ITD-F961L"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations, found in 25%\u201330% of acute myeloid leukemia (AML) patients, cause poor prognosis and resistance to FLT3 tyrosine kinase inhibitors (TKIs). We show that APG-115 selectively kills FLT3-ITD cells by activating p53. This critically upregulates TRIM22 (Tripartite motif-containing protein 22), an essential E3 ubiquitin ligase that directly binds FLT3-ITD, promotes its polyubiquitination, and induces its proteasomal degradation. This TRIM22-mediated mechanism offers a novel strategy to overcome intrinsic and acquired TKI resistance. Unlike inhibitors such as AC220, which suppress FLT3 signaling but downregulate p53, APG-115 restores p53 function and induces TRIM22, enabling potent synergy with FLT3 inhibitors. TRIM22 is essential for APG-115\u2019s suppression of leukemia stem cells, inducing cell cycle arrest, myeloid differentiation, and reduced clonogenic potential. The combination of APG-115 and AC220 significantly enhances apoptosis in FLT3-ITD AML models and primary cells, while sparing normal cells. It shows robust efficacy in preclinical xenograft models, reducing tumor burden and extending survival. This work establishes targeting the p53\/TRIM22 axis, reliant on TRIM22\u2019s unique activity against FLT3-ITD, as a highly promising therapeutic approach for FLT3-ITD AML, including resistant disease.<\/jats:p>","DOI":"10.1093\/lifemedi\/lnag017","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:21:58Z","timestamp":1778498518000},"source":"Crossref","is-referenced-by-count":0,"title":["TRIM22-mediated ubiquitin-dependent degradation of FLT3-ITD overcomes TKI resistance in acute myeloid leukemia"],"prefix":"10.1093","volume":"5","author":[{"given":"Meng","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaqin","family":"He","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoyin","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Wu","sequence":"additional","affiliation":[{"name":"Hongqiao International Institute of Medicine, Shanghai Tongren Hospital\/Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine , Shanghai 200025,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an 710061,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"2026070101564378500_lnag017-B1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1586\/17474086.2014.857596","article-title":"Allogeneic stem cell transplantation and targeted therapy for FLT3\/ITD+ acute myeloid leukemia: an update","volume":"7","author":"Hu","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"2026070101564378500_lnag017-B2","doi-asserted-by":"crossref","first-page":"e1500221","DOI":"10.1126\/sciadv.1500221","article-title":"Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia","volume":"1","author":"Green","year":"2015","journal-title":"Sci Adv"},{"key":"2026070101564378500_lnag017-B3","doi-asserted-by":"crossref","first-page":"e05384","DOI":"10.1002\/ccr3.5384","article-title":"Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS-like tyrosine kinase 3-internal tandem duplication with central nervous system involvement","volume":"10","author":"Suga","year":"2022","journal-title":"Clin Case Rep"},{"key":"2026070101564378500_lnag017-B4","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/s41375-022-01678-y","article-title":"Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia","volume":"36","author":"Koschade","year":"2022","journal-title":"Leukemia"},{"key":"2026070101564378500_lnag017-B5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.beha.2019.05.006","article-title":"Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia","volume":"32","author":"Wang","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"2026070101564378500_lnag017-B6","doi-asserted-by":"crossref","first-page":"108424","DOI":"10.1016\/j.bioorg.2025.108424","article-title":"Inhibition of FLT3-induced signalling in refractory acute myeloid leukaemia","volume":"160","author":"Yang","year":"2025","journal-title":"Bioorg Chem"},{"key":"2026070101564378500_lnag017-B7","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1021\/acsptsci.4c00071","article-title":"Structure-based optimization of pyrazinamide-containing macrocyclic derivatives as Fms-like tyrosine kinase 3 (FLT3) inhibitors to overcome clinical mutations","volume":"7","author":"Zheng","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2026070101564378500_lnag017-B8","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood.2019003538","article-title":"FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia","volume":"135","author":"Long","year":"2020","journal-title":"Blood"},{"key":"2026070101564378500_lnag017-B9","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1038\/s41467-023-41852-z","article-title":"Uri alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers","volume":"14","author":"Ding","year":"2023","journal-title":"Nat Commun"},{"key":"2026070101564378500_lnag017-B10","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1158\/1078-0432.CCR-24-2764","article-title":"Synergistic activity of combined FLT3-ITD and MDM2 inhibition with quizartinib and milademetan in FLT3-ITD mutant\/TP53 wild type acute myeloid leukemias","volume":"31","author":"Zhang","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026070101564378500_lnag017-B11","doi-asserted-by":"crossref","first-page":"101286","DOI":"10.1016\/j.xcrm.2023.101286","article-title":"A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment","volume":"4","author":"Long","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026070101564378500_lnag017-B12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4161\/cc.23031","article-title":"p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice","volume":"12","author":"Velasco-Hernandez","year":"2013","journal-title":"Cell Cycle"},{"key":"2026070101564378500_lnag017-B13","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1021\/acsmedchemlett.2c00402","article-title":"Development of gilteritinib-based chimeric small molecules that potently induce degradation of FLT3-ITD protein","volume":"13","author":"Ohoka","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"2026070101564378500_lnag017-B14","doi-asserted-by":"crossref","first-page":"e101436","DOI":"10.1371\/journal.pone.0101436","article-title":"In silico analysis of functional single nucleotide polymorphisms in the human TRIM22 gene","volume":"9","author":"Kelly","year":"2014","journal-title":"PLoS One"},{"key":"2026070101564378500_lnag017-B15","doi-asserted-by":"crossref","first-page":"e0000425","DOI":"10.1128\/jvi.00004-25","article-title":"The ELF3-TRIM22-MAVS signaling axis regulates type I interferon and antiviral responses","volume":"99","author":"Zhao","year":"2025","journal-title":"J Virol"},{"key":"2026070101564378500_lnag017-B16","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.3390\/cells10081864","article-title":"TRIM22. A multitasking antiviral factor","volume":"10","author":"Pagani","year":"2021","journal-title":"Cells"},{"key":"2026070101564378500_lnag017-B17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000327783","article-title":"Transcriptional response of MxA, PKR and SOCS3 to interferon-based therapy in HCV genotype 4-infected patients and contribution of p53 to host antiviral response","volume":"55","author":"Hamdi","year":"2012","journal-title":"Intervirology"},{"key":"2026070101564378500_lnag017-B18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bbrc.2014.10.067","article-title":"Type I interferon-mediated immune response against influenza a virus is attenuated in the absence of p53","volume":"454","author":"Zhu","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"2026070101564378500_lnag017-B19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.molimm.2019.02.005","article-title":"Tumor suppressor p53 inhibits porcine epidemic diarrhea virus infection via interferon-mediated antiviral immunity","volume":"108","author":"Hao","year":"2019","journal-title":"Mol Immunol"},{"key":"2026070101564378500_lnag017-B20","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cbin.10989","article-title":"TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K\/akt\/mTOR signaling pathway","volume":"42","author":"Li","year":"2018","journal-title":"Cell Biol Int"},{"key":"2026070101564378500_lnag017-B21","doi-asserted-by":"crossref","first-page":"e23367","DOI":"10.1002\/jbt.23367","article-title":"Bisphenol a prevents MCF-7 breast cell apoptosis via the inhibition of progesterone receptor transactivation","volume":"37","author":"Ogawa","year":"2023","journal-title":"J Biochem Mol Toxicol"},{"key":"2026070101564378500_lnag017-B22","doi-asserted-by":"crossref","first-page":"62069","DOI":"10.18632\/oncotarget.18911","article-title":"TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT\/GSK3beta\/beta-catenin signaling in non-small cell lung cancer","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"2026070101564378500_lnag017-B23","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1089\/jir.2006.0180","article-title":"Regulation of the interferon-inducible p53 target gene TRIM22 (Staf50) in human T lymphocyte activation","volume":"27","author":"Obad","year":"2007","journal-title":"J Interferon Cytokine Res"},{"key":"2026070101564378500_lnag017-B24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.leukres.2006.12.012","article-title":"Expression of the IFN-inducible p53-target gene TRIM22 is down-regulated during erythroid differentiation of human bone marrow","volume":"31","author":"Obad","year":"2007","journal-title":"Leuk Res"},{"key":"2026070101564378500_lnag017-B25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbrc.2013.10.110","article-title":"Down-regulation of tripartite-motif containing 22 expression in breast cancer is associated with a lack of p53-mediated induction","volume":"441","author":"Sun","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"2026070101564378500_lnag017-B26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.bbrc.2008.07.070","article-title":"Identification of TRIM22 as a RING finger E3 ubiquitin ligase","volume":"374","author":"Duan","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"2026070101564378500_lnag017-B27","doi-asserted-by":"crossref","first-page":"2518679","DOI":"10.1080\/23723556.2025.2518679","article-title":"TRIM22 promotes glioblastoma development by ubiquitinating bcl-2","volume":"12","author":"Zhang","year":"2025","journal-title":"Mol Cell Oncol"},{"key":"2026070101564378500_lnag017-B28","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1159\/000453192","article-title":"Bleomycin suppresses the proliferation and the mobility of human gastric cancer cells through the smad signaling pathway","volume":"40","author":"Liu","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"2026070101564378500_lnag017-B29","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3324\/haematol.2018.191650","article-title":"MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin","volume":"103","author":"Seipel","year":"2018","journal-title":"Haematologica"},{"key":"2026070101564378500_lnag017-B30","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3390\/genes16060684","article-title":"A modified FLT3 PCR assay using a TapeStation readout","volume":"16","author":"Blake","year":"2025","journal-title":"Genes (Basel)"},{"key":"2026070101564378500_lnag017-B31","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41375-022-01735-6","article-title":"An MDM2 degrader for treatment of acute leukemias","volume":"37","author":"Marcellino","year":"2023","journal-title":"Leukemia"},{"key":"2026070101564378500_lnag017-B32","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3109\/10428191003731325","article-title":"Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells","volume":"51","author":"Samudio","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"2026070101564378500_lnag017-B33","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1158\/1078-0432.CCR-13-1323","article-title":"Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia","volume":"19","author":"Baker","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026070101564378500_lnag017-B34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/biomedicines8080245","article-title":"Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"8","author":"Eguchi","year":"2020","journal-title":"Biomedicines"},{"key":"2026070101564378500_lnag017-B35","doi-asserted-by":"crossref","first-page":"107477","DOI":"10.1016\/j.bioorg.2024.107477","article-title":"Discovery of a potent gilteritinib-based FLT3-PROTAC degrader for the treatment of acute myeloid leukemia","volume":"149","author":"Ye","year":"2024","journal-title":"Bioorg Chem"},{"key":"2026070101564378500_lnag017-B36","doi-asserted-by":"crossref","first-page":"114792","DOI":"10.1016\/j.ejmech.2022.114792","article-title":"Modulation of FLT3-ITD and CDK9 in acute myeloid leukaemia cells by novel proteolysis targeting chimera (PROTAC)","volume":"243","author":"Reznickova","year":"2022","journal-title":"Eur J Med Chem"},{"key":"2026070101564378500_lnag017-B37","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/blood-2015-05-646497","article-title":"Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells","volume":"127","author":"Larrue","year":"2016","journal-title":"Blood"},{"key":"2026070101564378500_lnag017-B38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.bbamcr.2019.01.012","article-title":"Long lasting inhibition of Mdm2-p53 interaction potentiates mesenchymal stem cell differentiation into osteoblasts","volume":"1866","author":"Daniele","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"2026070101564378500_lnag017-B39","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2024025886","article-title":"FLT3 is genetically essential for ITD-mutated leukemic stem cells but dispensable for human hematopoietic stem cells","volume":"145","author":"Araujo","year":"2025","journal-title":"Blood"},{"key":"2026070101564378500_lnag017-B40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41375-022-01795-8","article-title":"Dual inhibition of CHK1\/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia","volume":"37","author":"Jiang","year":"2023","journal-title":"Leukemia"},{"key":"2026070101564378500_lnag017-B41","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-023-00911-w","article-title":"Treatment of older adults with FLT3-mutated AML: emerging paradigms and the role of frontline FLT3 inhibitors","volume":"13","author":"Short","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026070101564378500_lnag017-B42","doi-asserted-by":"crossref","first-page":"e0158290","DOI":"10.1371\/journal.pone.0158290","article-title":"Internal tandem duplication in FLT3 attenuates proliferation and regulates resistance to the FLT3 inhibitor AC220 by modulating p21Cdkn1a and Pbx1 in hematopoietic cells","volume":"11","author":"Abe","year":"2016","journal-title":"PLoS One"},{"key":"2026070101564378500_lnag017-B43","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41375-025-02589-4","article-title":"CircTADA2A stabilizes p53 via interacting with TRIM28 and suppresses the maintenance of FLT3-ITD acute myeloid leukemia","volume":"39","author":"Li","year":"2025","journal-title":"Leukemia"}],"container-title":["Life Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/lifemedi\/advance-article-pdf\/doi\/10.1093\/lifemedi\/lnag017\/68288782\/lnag017.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/lifemedi\/article-pdf\/5\/3\/lnag017\/68288782\/lnag017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/lifemedi\/article-pdf\/5\/3\/lnag017\/68288782\/lnag017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:23:21Z","timestamp":1782915801000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/lifemedi\/article\/doi\/10.1093\/lifemedi\/lnag017\/8678455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/lifemedi\/lnag017","relation":{},"ISSN":["2755-1733"],"issn-type":[{"value":"2755-1733","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,14]]},"article-number":"lnag017"}}